Should I Buy EYPT? EYPT 2026 Analysis

Should You Buy EyePoint Inc (EYPT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

13.300

1 Day change

4.48%

52 Week Range

19.110

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is breaking below near-term support with bearish momentum, and there are no near-term catalysts/news to force a quick rebound.
Oversold (RSI~14.8) can produce a bounce, but the setup is currently a falling-knife risk (MACD histogram negative and expanding).
Options are pricing extreme uncertainty (IV percentile ~98), which usually means the “easy money” is not in outright chasing shares here.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Bearish short-term trend; MACD histogram -0.378 and negatively expanding indicates downside momentum is strengthening.
RSI: RSI_6 = 14.776 (deep oversold) suggests a tactical dead-cat bounce is possible, but oversold alone is not a buy trigger while momentum keeps deteriorating.
Moving averages: Converging MAs suggests compression, but current momentum favors a breakdown/continuation lower rather than a clean reversal.
Levels: Pivot 14.443 is far overhead (now resistance). Key supports: S1 12.691 (already below it at ~12.33) and S2 11.608 (next downside area). Key resistances: 14.443, then 16.196.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: OI put/call 0.61 leans bullish (more calls than puts outstanding), but today’s volume is almost entirely puts (295 puts vs 0 calls), signaling near-term defensive trading.
Volatility: 30D IV ~193.76% with IV percentile 98.4 / IV rank 87.6 = extremely elevated; options are very expensive, implying the market expects large moves.
Activity: Today’s volume is ~21x the 30D average, and open interest appears elevated vs average (today vs OI avg ~178%), reinforcing “event-risk/high-uncertainty” conditions.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical mean-reversion potential: extremely oversold RSI can spark a short, sharp rebound if selling pressure exhausts.
- Analyst stance remains constructive (Mizuho Outperform; prior note called pullback a buying opportunity).
- Competitive read-through (per analyst commentary): Mizuho expressed greater comfort in EyePoint’s Phase 3 approach for Duravyu vs a competitor’s accelerated pathway, implying longer-term confidence (though not a near-term catalyst).

Neutral/Negative Catalysts

- Momentum is still worsening (MACD negative and expanding) and price is below S1 support (~~12.69), increasing odds of a push toward S2 (~~11.61).
- No news in the last week and no identified near-term catalyst; key clinical timelines (e.g., Phase 3 data mid-2026 per analyst context) are not aligned with a quick turnaround.
- Options imply extreme uncertainty (very high IV), often coinciding with unstable price action rather than clean trend reversals.
- Revenue and gross margin deterioration in latest reported quarter adds fundamental pressure while the story remains development-stage.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0.966M, -90.82% YoY (sharp contraction).
Profitability: Net income -59.732M (still deeply negative) but improved YoY (up 103.44% YoY as reported).
EPS: -0.85, improved 57.41% YoY (less negative).
Gross margin: 25.36%, down 72.73% YoY (material compression).
Overall: operating losses persist; reported YoY improvement in EPS is outweighed by collapsing revenue/margins for near-term sentiment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: Limited updates, but tone is supportive.
2025-11-11 (Mizuho): Viewed pullback as a buying opportunity; Outperform, $33 PT; said Q3 update was “fine” and Phase 3 programs on track.
2025-12-09 (Mizuho): Reiterated Outperform; noted competitor timeline risk but framed minimal negative read-through for EyePoint and emphasized confidence in Duravyu’s Phase 3 approach.
Wall Street pros: confidence in Duravyu program path and prior Phase 2 strength; sees pullbacks as entries.
Wall Street cons: long catalyst horizon (mid-2026 data context) and competitive/regulatory noise can keep the stock volatile without immediate upside follow-through.

6 Analyst Rating

Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.5 USD with a low forecast of 20 USD and a high forecast of 43 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.730

Low

Averages

31.5

High

Current: 12.730

Low

Averages

31.5

High

Mizuho

Graig Suvannavejh

Outperform

maintain

AI Analysis

2025-12-09

Reason

Mizuho

Graig Suvannavejh

Price Target

AI Analysis

2025-12-09

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh notes that Ocular Therapeutix (OCUL) recently announced its intent to accelerate the approval timeline for its sustained-release tyrosine kinase inhibitor/TKI, Axpaxli, by submitting an NDA off its Phase 3 SOL-1 study. For EyePoint (EYPT), with its first Phase 3 LUGANO data for Duravyu expected in mid-2026, this potentially positions an Axpaxli approval ahead of that for Duravyu, in a scenario the firm previously haven't assumed. That said, in Mizuho's view, even if Ocular's more aggressive regulatory approach succeeds, the firm sees a number of issues for the company and its Axpaxli. With this in mind, and its greater comfort in EyePoint's more thorough Phase 3 approach for Duravyu, along with the strength of the prior Phase 2 Duravyu data, the firm sees minimal read-throughs for EyePoint and remains Outperform-rated on the stock.

Mizuho

Graig Suvannavejh

maintain

$33

2025-11-11

Reason

Mizuho

Graig Suvannavejh

Price Target

$33

2025-11-11

maintain

Reason

Mizuho analyst Graig Suvannavejh views the recent pullback in shares of EyePoint as a buying opportunity. The company's Q3 update was "fine," with no major changes for lead asset Duravyu, the analyst tells investors in a research note. The firm says Duravyu remains on track in its two Phase 3 programs. Mizuho recommends buying the stock with an Outperform rating and $33 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EYPT

Unlock Now

EYPT Should I Buy

EYPT Should I Buy

Should You Buy EyePoint Inc (EYPT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch